Your browser doesn't support javascript.
loading
Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.
Even, Aniek J G; Hamming-Vrieze, Olga; van Elmpt, Wouter; Winnepenninckx, Véronique J L; Heukelom, Jolien; Tesselaar, Margot E T; Vogel, Wouter V; Hoeben, Ann; Zegers, Catharina M L; Vugts, Daniëlle J; van Dongen, Guus A M S; Bartelink, Harry; Mottaghy, Felix M; Hoebers, Frank; Lambin, Philippe.
Afiliação
  • Even AJ; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Hamming-Vrieze O; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Elmpt W; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Winnepenninckx VJ; Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Heukelom J; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Tesselaar ME; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Vogel WV; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hoeben A; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Zegers CM; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Vugts DJ; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • van Dongen GA; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
  • Bartelink H; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
  • Mottaghy FM; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hoebers F; Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Lambin P; Department of Nuclear Medicine, University Hospital, RWTH Aachen University, Aachen, Germany.
Oncotarget ; 8(3): 3870-3880, 2017 Jan 17.
Article em En | MEDLINE | ID: mdl-27965472
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioisótopos / Zircônio / Cetuximab / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Antineoplásicos Imunológicos / Neoplasias de Cabeça e Pescoço Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioisótopos / Zircônio / Cetuximab / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Antineoplásicos Imunológicos / Neoplasias de Cabeça e Pescoço Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos